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ABSTRACT

KEYWORDS

Objectives: The objective of the current study was to investigate the relationship between
changes in vital signs and intensive care unit (ICU) admission. Windsor Regional Hospital
treats 15–20 new patients a year with acute leukemia. These patients are at increased risk of
neutropenic fevers and admission to the ICU following induction chemotherapy.
Methods: Retrospective review examined the correlation between acute leukemia patient
vitals and ICU admission. The analysis included 37 patients: 7 ICU versus 30 controls.
Changes were compared to baseline over 24 hours prior to ICU admission or 5 days after
the initiation of induction chemotherapy in the following vital signs: heart rate (HR), mean
arterial pressure (MAP), temperature (T), respiratory rate (RR), and fraction of inspired
oxygen (FiO2) required to maintain a stable oxygen saturation.
Results: RR and FiO2 demonstrated signiﬁcant change over baseline leading up to ICU
admission within the ICU group. T, HR and MAP did not demonstrate signiﬁcant changes
over time in either group. RR, FiO2 and HR were signiﬁcantly higher in the ICU group at time
zero compared with the control group. RR was recorded least frequently in the 24 hours
leading up to ICU admission.
Discussion: Changes in RR and FiO2 predicted clinical deterioration requiring ICU admission in
acute leukemia patients. This is consistent with the predominant reason for ICU admission
which was respiratory failure.
Conclusion: We present preliminary evidence to support enhanced monitoring of RR and FiO2
in acute leukemia patients following induction chemotherapy with early intervention if
identiﬁed.

Acute leukemia; vital signs;
induction chemotherapy;
intensive care; respiratory
rate; acute myeloid
leukemia; hematological
malignancy

Introduction
Acute leukemia, including acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL), is a
cancer of the hematopoietic cells that is characterized
by an increased number of immature blood cells and
decreased production of blood components [1].
Patients with acute leukemia are treated with curative-intent, aggressive chemotherapy that requires
inpatient monitoring for an average of 28 days following initial induction chemotherapy. These patients
experience transfusion dependent anemia, thrombocytopenia and life-threatening neutropenia. While
younger patients tend to have a better prognosis, for
patients over the age of 65, about 70% will die
within one year of diagnosis [2].
Windsor Regional Hospital, a comprehensive acute
leukemia treatment center in Ontario, Canada, treats
15-20 patients with acute leukemia per year. Chemotherapy treatment consists of two phases: induction and consolidation therapy. Close monitoring of
patients during induction therapy is required due to
CONTACT Katharine McLaughlin

potential complications of neutropenic sepsis and
respiratory failure. Therefore, patients undergoing
acute leukemia treatment are admitted to the hospital and typically receive induction chemotherapy
within 5-7 days of diagnosis. The standard induction
regimen most often includes daunorubicin for 3
days with continuous infusion of cytarabine for 7
days, known as 3 + 7 [1]. After induction therapy,
patients remain in the hospital for approximately
four weeks for supportive care until their blood
counts recover.
Despite inpatient monitoring, mortality in patients
initially treated for acute leukemia, speciﬁcally AML,
can be as high as 60% depending on patient factors,
such as age, comorbidities and performance status,
and disease factors such as cytogenetics [3,4]. Complications such as neutropenic sepsis, respiratory dysfunction, and multi-organ failure can result in
admission to the intensive care unit (ICU) and eventually death. In a study of 83 AML patients admitted
to the ICU, greater than one half were admitted
during induction chemotherapy [5].
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Currently, patients undergoing induction chemotherapy are managed in the hospital. However,
there is increasing evidence suggesting that outpatient management might provide more beneﬁts to
quality of life, decreased infection risk and less cost
to the healthcare system [6–8]. In Ontario, induction
chemotherapy treatment for acute leukemia patients
costs the healthcare system approximately $1500 per
day with an average total cost per patient of $36,688,
and an average length of stay of 23.4 days [9].
During this time, patients are monitored, and vitals
are taken every four to twelve hours by nursing staﬀ.
If a patient is admitted to the ICU, the average cost
per day increases to $3000 per patient [10].
Studies have shown ICU survival rates of 32-66%,
and one-year survival post-ICU of 16-56% in acute leukemia patients [5,11,12]. This variability is likely due to
diﬀerences in patient characteristics and diﬀering
inclusion criteria between the studies. One study
reported after an ICU stay, 80% of patients with hematologic malignancy (including acute leukemia) maintained a good to excellent health-related quality of
life, and 80% were able to maintain the same therapeutic intensity of their cancer treatment regimen,
and were in partial or complete remission [13]. Therefore, acute leukemia patients can beneﬁt signiﬁcantly
from ICU admission.
However, multiple sources have demonstrated that
acute leukemia patients who do not require ICU admission have better outcomes than those who do [11].
Factors associated with poor ICU outcomes in acute leukemia patients include older age, requiring mechanical
ventilation, receiving a bone marrow transplant (BMT)
preparatory regimen, increased Simpliﬁed Acute Physiology Score (SAPS) II, increased Sequential Organ
Failure Assessment (SOFA) score, and increased Acute
Physiologic Assessment and Chronic Health Evaluation
(APACHE) II score [5,11,12,14]. Conversely, studies have
shown if patients with acute leukemia or hematological
malignancy are admitted to the ICU earlier, deﬁned as
within 24 hours of hospital admission or without
immediate life support, they have better outcomes
[13,15]. Worse outcomes in patients admitted to the
ICU later is likely due to more signiﬁcant changes in
physiological variables [16,17]. Therefore, determining
the correlation between patients’ vitals and admission
to the ICU would show if frequent monitoring of vital
signs and early intervention to manage changes
would lead to better patient outcomes. Additionally, frequent and accurate monitoring of vital signs and its
relationship to ICU admission in acute leukemia patients
is important in understanding ICU admission patterns.
To determine if there is a correlation between vital
sign changes and patient admission to the ICU, we
reviewed acute leukemia cases at our site spanning
the years 2015-2017. The speciﬁc aim of this study
was to determine which vital sign changes from

baseline are associated with ICU admission of acute
leukemia patients during the induction phase of
chemotherapy.

Methods
Study design and population
A retrospective chart review was conducted of all adult
patients (≥ 18 years of age) diagnosed with acute leukemia between 1 January 2015 to 31 December 2017
from the Windsor-Essex region.
Acute leukemia patients were categorized into ICU
and control groups. Patients were included in the
ICU group if they were admitted to the ICU during
their induction chemotherapy (Figure 1). Patients
were excluded from this group if they had been
admitted to the ICU prior to beginning induction chemotherapy. The control group consisted of patients
who had undergone induction chemotherapy and
were not admitted to the ICU during or after their
treatment. Any patients with partially missing records
or who did not undergo induction chemotherapy
were excluded from the study.

Figure 1. Inclusion and Exclusion Criteria. We reviewed the
medical records of 61 patients diagnosed with acute
myeloid leukemia in the years 2015-2017 treated at Windsor
Regional Hospital (WRH). Patients were included in the
study if they received induction chemotherapy, and were
either admitted to the Intensive Care Unit (ICU) during induction chemotherapy (ICU group) or were not (control group).
Patients were excluded if they did not receive induction chemotherapy, if they were admitted to the ICU prior to initiation
of induction chemotherapy, and if there were missing records.
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This study was approved by the Windsor Regional
Hospital Research Ethics Board.

Data analysis
For the ICU group, vital signs were analyzed during
the 24 hours prior to the patient’s admission to the
ICU. For the control group, the 24-hour period
leading up to midnight of the ﬁfth day after induction chemotherapy initiation (5 days post-induction)
was used for comparison. This time period was
chosen for comparison as patients in the ICU
group were admitted to the ICU an average of 5
days post-induction chemotherapy initiation. The
24-hour period was chosen for analyzing patient
vitals prior to ICU admission as these patients
demonstrated an acute decline in clinical status
prior to ICU admission. This window of time was
chosen to allow us to capture these acute
deteriorations.
Reason for ICU admission was reported as percentages. An unpaired T-test was done to compare the frequency of vitals recorded over the respective 24-hour
period in both groups. A one-way ANOVA test was
done to compare the proportion of isolated missed
vitals within the ICU group in the 24 hours prior to
ICU admission.
Temperature (T), mean arterial pressure (MAP), respiratory rate (RR), heart rate (HR) and fraction of
inspired oxygen (FiO2) were analyzed and graphed
over 24 hours in both groups. Mean arterial pressure
was calculated from standard systolic and diastolic
blood pressure (BP) measurements as follows: MAP =
[systolic + 2(diastolic)]/3. Fraction of inspired oxygen
was used to study the amount of oxygen delivered
to patients in order to maintain their oxygen saturation
(O2Sat) within normal range.
The dataset of vital signs over time falls in the
framework of longitudinal repeated measures data.
To analyze the data, we used linear mixed models,
which take into account the variations between
and within subjects as well as the diﬀerential frequency of measuring vitals in diﬀerent patients.
According to the linear mixed models, vital signs
were individually analyzed as functions of time
and a group variable. If a patient was admitted to
the ICU, ICU=1; otherwise ICU=0. This data analysis
was performed using lme4 and lmerTest packages
in R statistical analysis software [18]. Therefore,
vital signs were analyzed within each group to
identify if there were any signiﬁcant changes from
baseline over 24 hours, and also analyzed between
groups to identify any signiﬁcant diﬀerences at
time zero. Time zero is deﬁned as the time of ICU
admission in the ICU group, and midnight of day
5 post-induction in the control group.
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Results
Patient characteristics
We reviewed the medical records of 61 acute leukemia patients. Of the 37 included patients, 7 patients
were admitted to the ICU during induction chemotherapy, and 30 patients completed induction
chemotherapy without an ICU admission. Five
(71%) of the ICU patients had a diagnosis of AML,
and 2 (29%) had a diagnosis of acute promyelocytic
leukemia (APL), a type of AML. Twenty-ﬁve (83%) of
the control patients had a diagnosis of AML, 1 (3%)
had a diagnosis of APL, 3 (10%) had a diagnosis of
ALL, and 1 (3%) had undiﬀerentiated acute leukemia. In the ICU group 4 (57%) had a favorable risk
stratiﬁcation by genetics, and in the control group
10 (33%) were favorable [19]. The mean age at diagnosis of the ICU group was 51 years (median 49
years), and the mean age at diagnosis of the
control group was 63 (median 66 years). Statistically,
there was no signiﬁcant age diﬀerence between the
two groups (p=0.07). Six (87%) of the ICU patients
were female, and 14 (47%) of the control patients
were female. The median Charlson score was 3
(ranging from 2-6) for the ICU group, and 5
(ranging from 2-8) for the control group. The
median number of days patients spent in the ICU
was 11, ranging from 1 to 27. Four (57%) of the
ICU patients died in the ICU during their admission
for induction chemotherapy, and two (7%) of the
control patients died during their hospital admission
for induction chemotherapy. Detailed patient characteristics are shown in Table 1 and Appendix1.

Reason for ICU admission
We examined the ICU records and progress notes of
the ICU group. Reason for ICU admission was
Table 1. Patient characteristics for ICU and control groups.
Total
Median Age
Sex
Male
Female
Diagnosis
AML
APL
ALL
Undiﬀerentiated
Risk Stratiﬁcation by Genetics
Favorable
Intermediate
Adverse
Unknown
Prior Induction
Median Charlson Score
Deceased During Induction
In ICU
On Medical Floor
Median Days in ICU

ICU

Control

7
49 (38-64)

30
66 (17-89)

1 (13%)
6 (87%)

16 (53)
14 (47%)

5 (71%)
2 (29%)
0 (0%)
0 (0%)

25 (83%)
1 (3%)
3 (10%)
1 (3%)

4 (57%)
2 (29%)
1 (13%)
0 (0%)
1 (14%)
3 (2-6)

10 (33%)
13 (43%)
4 (13%)
3 (10%)
0 (0%)
5 (2-8)

4 (57%)
0 (0%)
11 (1-27)

N/A
2 (7%)
N/A
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Figure 2. Reasons for ICU Admission: Cause for Intensive Care Unit (ICU) admission was interpreted based on ICU records; in some
patients multiple reasons for admission were listed. ICU admission was predominantly related to respiratory failure.

interpreted based on these records (Figure 2). In some
instances, there were multiple reasons for admission
listed. 85.71% of patients were admitted for respiratory
failure, 57.14% were admitted due to infection, 14.29%
were admitted for cardiac arrest, and 14.29% were
admitted for acute kidney injury. Out of 6 patients
admitted for respiratory failure, four were secondary
to infection, one was secondary to all-trans retinoic
acid (ATRA) syndrome, and one did not have any
underlying cause listed.

Frequency of recorded vitals
The comparison of the frequency of recorded vitals
between the two groups was performed using a Ttest (Figure 3). The average number of vitals recorded
in the ICU group in the 24 hours before ICU admission

was 8.86, and the average number of vitals recorded in
the control group in the 24 hours 5 days post-induction was 2.67. There was no signiﬁcant diﬀerence
between the two groups (p = 0.07).

Isolated missed vitals
If a set of vitals at a speciﬁc timepoint was missing one or
more of the standard vital signs (T, BP, RR, HR, O2Sat), the
missing vital signs were considered to be ‘isolated missed
vital signs’. In patients of the ICU group, we compared
the number of times each vital sign was missed to the
total number of vitals taken and reported it as a percentage (Figure 4). The average percentage of isolated
missed vital signs are as follows: BP, 16.8%, RR, 26.0%,
HR, 19.3%, O2Sat, 15.2% and T, 43.6%. Temperature
was excluded from graphing and statistical analysis as

Figure 3. Average Number of Vitals Taken: There is no signiﬁcant diﬀerence in the average number of times vital signs were taken
over the 24 hour study period between the Intensive Care Unit (ICU) group and the control group (p = 0.07).

HEMATOLOGY
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Figure 4. Isolated Missed Vital Signs: ‘Isolated missed vital signs’ refers to instances where a set of vitals taken at a certain point in
time was missing one or more of the standard vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation). Temperature was excluded from this analysis as it is not recorded on Intensive Care Unit (ICU) consult forms. Respiratory rate was
recorded the least during 24 hours leading up to ICU admission, though this was not statistically signiﬁcant (p = 0.87).

it is not recorded on ICU consult forms, which were used
for documentation in at least three patients. Therefore, it
artiﬁcially inﬂated the number of missed temperature
readings. While the diﬀerence was not statistically signiﬁcant [F(3, 24) = 0.23, p = 0.87], RR was recorded the least
number of times during the 24 hours before ICU admission when compared to HR, BP and O2Sat (Table 2).

Changes in vital signs
During the 24 hours before ICU admission, RR and FiO2
demonstrated considerable change from baseline
within the ICU group in comparison with T, BP, and
HR (Figures 5 and 6). This change was not observed
in the control group.
Fraction of inspired oxygen demonstrated signiﬁcant increases from baseline over time leading up to
ICU admission within the ICU group (Figures 5E,
Figure 6A). For every hour closer to ICU admission,
FiO2 would increase 0.023 units on average (95% CI:
0.017 - 0.029). Changes from baseline in FiO2 over
time were not signiﬁcant in the control group (p =
0.946). The diﬀerence in FiO2 between ICU and
control groups at time zero was 0.33 (95% CI: 0.23 0.43, p < 0.0001).
Similar results were observed in RR measurements
(Figures 5D, Figure 6B). In the ICU group, for every
hour closer to ICU admission time, RR increased an
average of 0.60 breaths per minute (95% CI: 0.62 0.58). In control patients, there was no signiﬁcant
change in RR over time. The diﬀerence in RR
between ICU and control groups at time zero was
14.20 breaths per minute (95% CI: 11.82 -16.58, p <
0.0001).

While there was no signiﬁcant change from baseline over time in HR within the ICU group (p > 0.12)
or control group, there was a signiﬁcant diﬀerence
between the two groups at time zero (Figure 5C,
Figure 6C). The diﬀerence in average HR between
the two groups at the time of admission was 31
beats per minute (95% CI: 18.01 - 43.99, p <
0.00008).
There were no signiﬁcant changes from baseline in
MAP or T over time in either group, and there was no
signiﬁcant diﬀerence in MAP or T between the two
groups at time zero. Neither was clinically predictive
of decline or ICU admission (Figure 5A and B).

Discussion
In the current retrospective study, we observed that
changes in RR and FiO2 are the most predictive vital
signs for ICU admission in acute leukemia patients
during induction chemotherapy. The signiﬁcant
changes over baseline and increased value at the
time of ICU admission in FiO2 and RR are essential for
informing patient care, including more frequent monitoring of these vitals when changes over baseline are
ﬁrst noticed, followed by timely intervention. Literature reviews showed that there was minimal previous
research on the predictive value of recorded vital
signs in acute leukemia patients. Respiratory events
in general and speciﬁcally RR > 25 breaths/minute
was previously found to be predictive of death by
day 45 post treatment in acute leukemia patients
[20]. These respiratory events can occur in >80% of
patients within 10 days if they have a diagnosis of
AML [21].
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Table 2. Results of One-way ANOVA test, comparing the proportion of isolated missed vital signs for blood pressure (BP),
respiratory rate (RR), heart rate (HR), and oxygen saturation (O2Sat).
Summary
Groups
Missed BP
Missed RR
Missed HR
Missed O2Sat
ANOVA
Source of Variation
Between Groups
Within Groups
Total

Count

Sum

Average

Variance

7
7
7
7

1.178716
1.818362
1.351263
1.065152

0.168388
0.259766
0.193038
0.152165

0.017673
0.119976
0.045216
0.086321

SS
0.047114
1.615115

df
3
24

MS
0.015705
0.067296

F
0.233364

1.662229

27

Due to the high mortality associated with AML
speciﬁcally, monitoring vital signs that could predict
if a patient will require ICU admission is imperative.
This frequent vitals monitoring is particularly important as a previous study has shown that AML patients
have better outcomes when they are admitted to the
ICU earlier due to complications of treatment [15]. A
study conducted on patients with hematologic malignancy, where AML patients made up 27% of their study
population, showed signiﬁcantly higher ICU survival if
patients are admitted to the ICU within 24 hours of
hospital admission [13]. Other studies have shown
that admission to the ICU for acute respiratory failure
was not signiﬁcantly associated with a poor outcome,
though this may have been due to the selection criteria of the study or use of non-invasive mechanical
ventilation as a ﬁrst-line ventilation support [20].
However, previous studies have shown that 47-54%
of acute leukemia patients admitted to the ICU
required intubation [5,12] and 5% required tracheostomy, indicating invasive mechanical ventilation is a

P-value
0.872222

F crit
3.008787

common requirement amongst this patient population
[12]. This is important to note, as invasive mechanical
ventilation has been shown to be associated with
increased ICU mortality in acute leukemia patients
[5,12,14] and patients with hematologic malignancy
[13,17]. Consequently, if invasive mechanical ventilation is avoided, ICU mortality is decreased [5,12].
Interestingly, RR was the most frequent isolated
missed vital sign over the 24 hours prior to ICU admission in the ICU group compared to heart rate, blood
pressure and oxygen saturation. Respiratory rate is a
diﬃcult vital sign to measure, as it requires a healthcare provider to watch for chest expansion and manually count the number of breaths over 10-15 seconds.
Respiratory rate measurement is time consuming and
labor-intensive compared to other vitals monitored
electronically such as BP, HR and O2Sat. These diﬀerences in measuring RR may account for why it is
missed more frequently. The fact that RR is manually
measured as opposed to electronically also introduces
increased risk for human error. However, the data

Figure 5. Patient Vitals Over 24 Hours: Patient temperature (A), mean arterial pressure (MAP) (B), heart rate (C), respiratory rate
(RR) (D) and fraction of inspired oxygen (FiO2) (E) as measured during the 24 hours prior to Intensive Care Unit (ICU) admission or 5
days post-induction chemotherapy initiation. Increases in RR (D) and FiO2 (E) occur in the 24 hours prior to ICU admission, but are
not observed in the control group. Each line corresponds to a single patient, and each point corresponds to when the respective
vital sign was checked by nursing staﬀ. Control group, n = 30, ICU group, n = 7.
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Figure 6. Changes in Vital Signs Over Time: Fraction of inspired oxygen (FiO2) (A) and respiratory rate (RR) (B) show signiﬁcant
increases from baseline over 24 hours prior to Intensive Care Unit (ICU) admission within the ICU group. Changes in heart rate (HR)
(C) over the same time period is not signiﬁcant within the ICU group. However, there were signiﬁcant diﬀerences in FiO2 (A), RR (B)
and HR (C) between the ICU group and control group at time zero (p<0.0001). Time zero is deﬁned as the time of ICU admission in
the ICU group, or midnight on day 5 post-induction chemotherapy initiation in the control group.

presented in this study suggest that RR is an essential
vital sign to monitor in the acute leukemia, speciﬁcally
AML, patient population.
Respiratory failure was the most common reason for
admission to the ICU in this patient population, compared to fever, cardiac, or renal causes. Previous
studies agreed that one of the most frequent reasons
for ICU admission in acute leukemia patients was respiratory dysfunction, accounting for between 31-82%
of
admissions
depending
on
the
study
[5,11,12,21,22]. Another study showed approximately
9% of newly diagnosed AML patients developed
Acute Respiratory Distress Syndrome (ARDS) within
their ﬁrst 15 days of admission [23]. This ﬁts with the
picture that RR and FiO2 are the most predictive vital
signs in determining the likelihood of a patient
needing to be admitted to the ICU. Therefore, it
shows that increased attention should be paid to
monitoring respiratory rate and oxygen needs in
acute
leukemia
patients
during
induction
chemotherapy.
Acute leukemia patients admitted to the ICU were
shown to have a persistently elevated HR in the
24 hours before ICU admission. This leads us to consider closer monitoring of this patient population.
Underlying comorbidities may be a cause of this
ﬁnding, but further research is warranted to investigate why patients in the ICU group consistently have
a higher HR at baseline.
Based on vital sign analysis, temperature was well
monitored by nurses on the inpatient ﬂoor. In the
24 hours prior to ICU admission or 5-day post-induction in the control group, there appeared to be no
diﬀerence in temperature between groups. Though
patients from both groups would occasionally have
fevers throughout their inpatient stay, these fevers
seemed to be identiﬁed and treated quickly, with
patient temperature often varying dramatically
between time points.

Limitations
One of the main limitations of this study is the small
population of acute leukemia patients treated at our
site, a community hospital with lower patient
volumes. This led to an even smaller sample size
after exclusion. This small sample size may reduce
the validity of the statistical analysis, and allow
limited transferability of these results to other patient
populations or healthcare facilities. Additionally, as
this is a single center study conducted in WindsorEssex County, lifestyle and demographic factors
speciﬁc to this region could inﬂuence results.
However, for the purposes of quality improvement in
the care of this speciﬁc patient population, the
results suggest that there is clinical signiﬁcance in
changes in FiO2 and RR.
Possible confounding variables include comorbidities such as diabetes, chronic obstructive pulmonary
disease (COPD), obesity, and hypertension, and lifestyle choices, such as smoking and alcohol use. Comorbidities within the two groups were not compared in
this study due to lack of standardized reporting and
access to health information. However, patients with
these conditions or risk factors may be more likely to
deteriorate clinically with inferior outcomes, and their
vital signs predictive of ICU admission could be
related to those underlying conditions. Respiratory
events as deﬁned by one study occurred more often
in patients with a smoking history or previous lung
disease [20,24]. Comorbidities speciﬁcally linked to
increased risk of ICU admission were cerebrovascular,
hepatic and lung disease [24]. Increased number of
comorbidities elevated the risk of ICU admission [24].
Patients would have also received a variety of medications while in hospital in addition to chemotherapy,
including antibiotics, analgesics, or medications
related to comorbidities. These treatments could also
impact a patient’s overall condition and whether
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they require intensive care. For example, the use of
vasopressors is related to poor ICU outcomes [11,14].

Future data analysis
Vital signs could be analyzed and graphed for a more
extended time period prior to ICU admission. In particular, an extended analysis could provide additional
information regarding HR, as it is signiﬁcantly elevated
in the ICU group at the time of ICU admission but did
not show a signiﬁcant increase over time within the 24hour time period analyzed in this study. As discussed
above, there may be speciﬁc comorbidities or underlying health conditions that put some acute leukemia
patients at higher risk for admission to the ICU. It
may be beneﬁcial to analyze comorbidities and the
reason for admission to the ICU in more detail in
order to identify higher risk patient populations for
ICU admission. These patients may need closer monitoring for signs indicative of intensive care requirements. To further understand health outcomes in this
patient population, future studies could extend the
monitoring time period to allow for assessment of
course in ICU and overall survival as they relate to
changes in vital signs.

Conclusions
Respiratory rate and FiO2 increases over baseline
within 24 hours prior to ICU admission were statistically signiﬁcant, suggesting that changes in these
vital signs are the most predictive of ICU admission
in acute leukemia patients receiving induction chemotherapy. Therefore, these vital signs should be monitored frequently and accurately in this population so
early intervention is instituted prior to clinical deterioration. Protocols should require urgent respirology
and, when applicable, infectious disease consultation,
for patients with changes to RR or FiO2 from baseline.
This information will be necessary for the improved
outcome in these patients being treated with curative
intent.
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analog clocks in hospital rooms must be implemented.
The development of novel methodologies for more
accurate and practical measurements of RR will
decrease potential for human error and allow for RR
measurements to be more standardized like other
vital signs monitored electronically.
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Appendix: Patient Demographics
ICU patients

Patient
ID (ICU)

Age

Sex

Diagnosis

Molecular

1

64

F

APL

2

38

F

AML

3

53

F

AML

4

44

M

APL

FLT3
Positive
NPM1
Positive
NPM1
Positive,
FLT3
Positive
PML-RARA
Positive

5
6
7

62
49
46

F
F
F

AML
AML
AML

Prior therapies

Charlson
score

Deceased
during
induction

Duration
in ICU
(days)

Thyroidectomy for
malignancy
Rosacea, eczema

6

No

12

2

In ICU

13

FLAG

Mood disorder

3

No

11

ATRA, arsenic

Previous heart
transplant (on
cyclosporine),
hypertension,
diabetes, gout, obesity
None
None
Crohn’s disease,
H. pylori, gastric reﬂux,
carpal tunnel, B12
deﬁciency

3

in ICU

1

4
2
3

In ICU
No
In ICU

11
27
3

Charlson
Score

Deceased
During
Induction

5

No

Induction
chemotherapy

Comorbidities

Idarubicin,
ATRA induction
7+3
3 + 7;ARA-C for
consolidation

7+3
5+3
7+3

NPM1
Positive,
FLT3
Positive

Control patients
Patient
ID
(Control)

Age

Sex

Diagnosis

Molecular

1

77

F

AML

complex
karyotype

7 + 3; vidaza

2

49

M

AML-M2

7+3

3

78

F

AML

AML-ETO
Positive
NPM1
Positive, FLT3
Positive

4

55

F

ALL

5

51

M

AML

6

72

F

AML-M2

Del 5q,
complex
karyotype
FLT3 Positive

7

68

M

AML

Trisomy 11

ARA-C

8
9

57
66

M
F

AML
AML

FLT3 Positive
NPM1
Positive

10
11

77
27

M
M

12

65

M

AML-M1
Acute leukemia
(undiﬀerentiated)
AML-M2

13

89

F

14

58

15
16
17

40
67
80

Prior
Therapies

Induction
Chemotherapy

Comorbidities
Aortic stenosis,
hypertension, osteoarthritis,
mild pulmonary
hypertension
Coronary artery disease,
diabetes
None

4

No

5

No

Previous breast cancer

5

No

Bacterial endocarditis, left
hip replacement, diabetes

4

No

6

No

5

Yes

7+3
5+2

Gastric reﬂux, hypertension,
hypothyroidism, gout
Abdominal aortic aneurysm,
pulmonary embolism,
perirectal abscess,
hypercholesterolemia, atrial
ﬁbrillation
Hypertension
Hypertension, arthritis

3
4

No
No

5+2
ALL COG 1131

Hypertension
Hypothyroidism

5
2

No
No

AML-ETO
Positive

7+3

6

No

AML-M1

NPM1
Positive

hydroxyurea

8

Yes

F

AML

NPM1
Positive, FLT3
Positive

FLAG-Ida

Cirrhosis, diabetes,
hypertension, anxiety,
hyperthyroidism
Hypertension, osteoarthritis,
anxiety, irritable bowel
syndrome, dementia,
congestive heart failure
None

3

No

M
F
F

AML
AML
AML

2
5
6

No
No
No

FLT3 Positive

7+3

Vidaza for
underlying
MDS

Hyper CVAD /
Blinatumumab
7+3
5+2

FLAG-Ida
FLAG-Ida
7+3

None
Herpes, Gastric reﬂux

(Continued)
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Continued.
Patient
ID
(Control)

Age

Sex

Diagnosis

Molecular

Prior
Therapies

Induction
Chemotherapy

7+3
ATRA/ Arsenic

18
19

75
50

M
M

AML
APL

20

50

M

AML

21

69

M

AML-M2

22

74

M

AML

23

69

M

AML

24
25

55
72

F
F

AML
ALL

26

65

F

AML

FLAG-Ida

27
28

17
63

F
M

ALL
AML

AALL 1131
7+3

29

66

M

AML

30

80

F

AML

PML-RARA
Positive

7+3
AML-ETO
Positive
Trisomy 8

7+3
7+3
7+3

B-cell lineage
monoclonal
proliferation

CBF8-MYH11
Positive

7+3
Dana Farber

7+3

5+2

Comorbidities

Charlson
Score

Deceased
During
Induction

Spinal stenosis,
osteoporosis,
Diabetes, hypertension
None

6
3

No
No

Diabetes, obstructive sleep
apnea, morbid obesity
None

3

No

4

No

Diabetes, obstructive sleep
apnea
Melanoma, hip
replacement, bilateral
femoral angioseal stents,
hypertension
Anxiety
Diabetes, hypertension,
basal cell carcinoma, gastric
reﬂux, dyslipidemia,
glaucoma, abdominal
hernia
Polycythemia rubra,
previous breast cancer
None
Follicular lymphoma, gastric
reﬂux
Aortic aneurysm repair,
hypertension, IgA
nephropathy, coronary
artery disease
Hypercholesterolemia,
gastric reﬂux, hypothyroid

6

No

7

No

3
7

No
No

6

No

2
5

No
No

7

No

7

No

